May 28, 2020

Advanced Proteome Therapeutics Announces First Results of Pilot Project

2021-09-09T13:12:25-04:00

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce that it’s US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), has received first results as part of its collaborative pilot project with a promising Boston based biotechnology company (“Biotech”), as announced on February 10, 2020. The pilot project is testing APTI’s site specific conjugation technology with Biotech’s proprietary antibody against a high-value target.

Advanced Proteome Therapeutics Announces First Results of Pilot Project2021-09-09T13:12:25-04:00
May 26, 2020

Advanced Proteome Therapeutics Announces Options Grant

2021-09-09T13:19:02-04:00

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), announces that it has granted 150,000 incentive stock options to a consultant to the company as per an agreement dated February 26, 2020, in accordance with the provisions of its 10% rolling stock option plan. The incentive stock options have an exercise price of $0.09 per share, are valid for a 2-year period from the date of grant, and are subject to regulatory approval.

Advanced Proteome Therapeutics Announces Options Grant2021-09-09T13:19:02-04:00
May 22, 2020

Advanced Proteome Therapeutics Announces Closing of Non-Brokered Private Placement

2021-09-09T13:22:08-04:00

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) is pleased to announce that, further to its news release of February 24, 2020 and subject to the approval of the TSX Venture Exchange, it has closed a non-brokered private placement (the “Private Placement”) raising gross proceeds of $340,565.34 by the issuance of 5,676,089 units at a price of $0.06 per unit.

Advanced Proteome Therapeutics Announces Closing of Non-Brokered Private Placement2021-09-09T13:22:08-04:00
May 20, 2020

Advanced Proteome Therapeutics Announces Warrant Extension and Repricing

2021-09-09T13:25:11-04:00

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) announces that, subject to the approval of the TSX Venture Exchange (the “Exchange’), it wishes to amend the exercise price and expiration of certain outstanding warrants (the “Warrants”). The Warrants’ exercise price and expiry date are detailed below. Each of these Warrants will be amended to reflect an exercise price of $0.10 each. In accordance with Exchange policies, the Warrants will also be amended to include an acceleration clause whereunder the exercise period of Warrants will be reduced to thirty (30) days, if for any ten consecutive trading days during the unexpired term of the Warrants, the closing price of the Company’s listed shares exceeds the price of $0.125 cents per share.

Advanced Proteome Therapeutics Announces Warrant Extension and Repricing2021-09-09T13:25:11-04:00
Go to Top